Cite
HARVARD Citation
Jaramillo, S. et al. (2021). Ruxolitinib is effective in the treatment of a patient with refractory T‐ALL. EJHaem. 2 (1), pp. 139-142. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Jaramillo, S. et al. (2021). Ruxolitinib is effective in the treatment of a patient with refractory T‐ALL. EJHaem. 2 (1), pp. 139-142. [Online].